PetIQ reports 4Q loss

Associated Press |

EAGLE, Idaho (AP) _ PetIQ Inc. (PETQ) on Tuesday reported a loss of $3.3 million in its fourth quarter.

On a per-share basis, the Eagle, Idaho-based company said it had a loss of 25 cents. Earnings, adjusted for pretax expenses and costs related to mergers and acquisitions, were 21 cents per share.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 7 cents per share.

The pet medications and products maker posted revenue of $51.9 million in the period, also exceeding Street forecasts. Five analysts surveyed by Zacks expected $51.6 million.

PetIQ expects full-year revenue in the range of $450 million to $500 million.

PetIQ shares have increased slightly more than 4 percent since the beginning of the year.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETQ at https://www.zacks.com/ap/PETQ

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…